Observational Study to Understand Patients' and Physicians' Attitudes to Statins in TurkeY (STAY)
8. januar 2014 oppdatert av: AstraZeneca
In Turkey statin compliance is lower than EU countries.
(EURIKA).
We will assess the underlying causes of statin incompliance.
The investigators will build patient and physician education programs to improve compliance in TURKEY.
Our aim is to assess patients' and physicians' attitudes to statins by mean of HABIT Patient and Physician survey respectively.
Studieoversikt
Status
Fullført
Forhold
Detaljert beskrivelse
Observational study to understand patients' and physicians' attitudes to Statins in TurkeY
Studietype
Observasjonsmessig
Registrering (Faktiske)
500
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Ankara, Tyrkia
- Research Site
-
Aydin, Tyrkia
- Research name
-
Diyarbakir, Tyrkia
- Research Site
-
Hatay, Tyrkia
- Research Site
-
Istanbul, Tyrkia
- Research Site
-
Izmir, Tyrkia
- Research Site
-
K. Maras, Tyrkia
- Research Site
-
Kayseri, Tyrkia
- Research Site
-
Malatya, Tyrkia
- Research Site
-
Manisa, Tyrkia
- Research Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Patients > 18 years of age, diagnosed with hypercholesterolemia and prescribed with at least one statin irrespective of its type and/or dose.
The inclusion period will last 6 months, on which consecutive patients attending the outpatient Family Physicians or Cardiologists office will be invited to participate.
Beskrivelse
Inclusion Criteria:
- Provision of subject informed consent Female and/or male aged over 18 years,
- Diagnosis of hypercholesterolemia according to ICD-10 classification
- Receiving at least one prescription of one statin during the last 12 months and to be an outpatient.
Exclusion Criteria:
- Receiving statin at the time of admittance
- Patients unable to read and/or understand the study questionnaires
- Pregnant women,
- Patients participating in randomized clinical trials and patients included in this study once
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
HABIT scores for the patients of the following questionnaire items (see description)
Tidsramme: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
|
|
Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
|
|
HABIT scores for the physicians of the following questionnaire items (see description)
Tidsramme: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
|
|
Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Socio-demographics terms
Tidsramme: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
|
|
Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
|
|
Clinical characteristics
Tidsramme: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
|
|
Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
|
|
Clinical characteristics (continuation)
Tidsramme: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
|
|
Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studieleder: Mujgan Ates, DR, AZ MC Turkey
- Hovedetterforsker: Ramazan Ozdemir, PROF.DR., Inonu University Faculty of Medicine, Cardiology Department
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. doi: 10.1001/jama.285.19.2486. No abstract available.
- Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med. 2009 Oct;122(10):961.e7-13. doi: 10.1016/j.amjmed.2008.12.021. Epub 2009 Jun 26.
- Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000 Feb 28;160(4):459-67. doi: 10.1001/archinte.160.4.459.
- Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008 Apr;155(4):772-9. doi: 10.1016/j.ahj.2007.12.011.
- Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. doi: 10.1016/j.jacc.2004.07.001.
- Ertas FS. [Statins with a perspective of lifelong therapy]. Turk Kardiyol Dern Ars. 2009 Mar;37 Suppl 2:29-36. Turkish.
- Tokgozoglu L, Kaya EB, Erol C, Ergene O; EUROASPIRE III Turkey Study Group. [EUROASPIRE III: a comparison between Turkey and Europe]. Turk Kardiyol Dern Ars. 2010 Apr;38(3):164-72. Turkish.
- Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM; West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007 Oct 11;357(15):1477-86. doi: 10.1056/NEJMoa065994.
- Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002 Jul 24-31;288(4):455-61. doi: 10.1001/jama.288.4.455.
- Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010 Feb;41(2):397-401. doi: 10.1161/STROKEAHA.109.566950. Epub 2010 Jan 14.
- Lardizabal JA, Deedwania PC. Benefits of statin therapy and compliance in high risk cardiovascular patients. Vasc Health Risk Manag. 2010 Oct 5;6:843-53. doi: 10.2147/VHRM.S9474.
- Yang Y, Thumula V, Pace PF, Banahan BF 3rd, Wilkin NE, Lobb WB. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther. 2009 Oct;31(10):2178-88; discussion 2150-1. doi: 10.1016/j.clinthera.2009.10.002.
- Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, Avorn J, Solomon D, Brookhart MA, Choudhry NK. Patient, physician, and payment predictors of statin adherence. Med Care. 2010 Mar;48(3):196-202. doi: 10.1097/MLR.0b013e3181c132ad.
- Foley KA, Vasey J, Berra K, Alexander CM, Markson LE. The Hyperlipidemia: Attitudes and Beliefs in Treatment (HABIT) survey for patients: results of a validation study. J Cardiovasc Nurs. 2005 Jan-Feb;20(1):35-42. doi: 10.1097/00005082-200501000-00008.
- Foley KA, Vasey J, Alexander CM, Markson LE. Development and validation of the hyperlipidemia: attitudes and beliefs in treatment (HABIT) survey for physicians. J Gen Intern Med. 2003 Dec;18(12):984-90. doi: 10.1111/j.1525-1497.2003.30114.x.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. oktober 2012
Primær fullføring (Faktiske)
1. desember 2012
Studiet fullført (Faktiske)
1. desember 2012
Datoer for studieregistrering
Først innsendt
19. juni 2012
Først innsendt som oppfylte QC-kriteriene
21. juni 2012
Først lagt ut (Anslag)
22. juni 2012
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
9. januar 2014
Siste oppdatering sendt inn som oppfylte QC-kriteriene
8. januar 2014
Sist bekreftet
1. januar 2014
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NIS-CTR-XXX-2012/1
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .